On April 21, 2025, Ascentage Pharma announced that two of its proprietary novel drugs, lisaftoclax (APG-2575) and olverembatinib (HQP1351), have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax is included for the diagnosis and treatment of lymphoid malignancies, while olverembatinib is included for leukemias in children and adolescents.
The CSCO Guidelines are influential in clinical practice in China, and their inclusion of Ascentage Pharma's drugs validates their clinical value and therapeutic potential. This recognition supports the broader adoption and commercialization of these key assets.
This milestone underscores Ascentage Pharma's commitment to addressing unmet medical needs in oncology and strengthens the market positioning of its innovative pipeline in China. The guidelines provide a framework for clinicians, potentially increasing patient access to these therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.